E1411, An Intergroup Randomized Phase II Four Arm Study In Patients >/= 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB / R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV/ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB / LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV / LR)

Prognostic impact of mantle cell lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

C Ryan;V Wang;M Smith;B Till;S Parekh;D Yang;L Kostakoglu Shields;N Samad;O Jegede;R Little;J Friedberg;J Leonard;B Kahl;P Martin ASH Annual Meeting (December 6-9, 2025, Orlando, FL). Abstract 3581 poster. Blood (2025) 146 (Supplement 1): 3581

Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma

M Smith;O Jegede;P Martin;B Till;S Parikh;D Yang;E Hsi;T Witzig;S Dave;D Scott;C Hanson;L Kostakoglu Shields;M Crump;C Casulo;N Bartlett;P Fabrizio Caimi;T Al Baghdadi;K Maddocks;M Romer;D Inwards;R Lerner;L Wagner;R Little;JW Friedberg;JP Leonard;B Kahl Blood May 31:blood.2024023962. doi: 10.1182/blood.2024023962. Online ahead of print

PMid: PMID38820500

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

M Smith;O Jegede;P Martin;B Till;S Parekh;D Yang;L Kostakoglu Shields;C Casulo;N Bartlett;P Caimi;T Al Baghdadi;K Maddocks;M Romer;D Inwards;R Lerner;L Wagner;R Little;JW Friedberg;J Leonard;B Kahl ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), oral presentation

E1411 Randomized Phase 2 Trial of Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma: Addition of Bortezomib to Front-Line BR Induction does not prolong PFS

MR Smith;O Jegede;P Martin;B Till;S Parekh;D Yang;L Kostakoglu Shields;C Casulo;N Bartlett;P Caimi;T Al Baghdadi;K Maddocks;M Romer;D Inwards;R Lerner;L Wagner;R Little;J Friedberg;J Leonard;B Kahl J Clin Oncol 39, 2021 (suppl 15; abstr 7503) (American Society of Clinical Oncology Annual Meeting 2021, oral)

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

M Smith;O Jegede;SS Parekh;C Hanson;F Kuhr;P Martin;B Till;M Crump;JP Leonard;JW Friedberg;B Kahl;T Witzig Blood (2019) 134 (Supplement_1): 751, abst 623; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral